<clinical_study>
<study_id>
<org_name>
  NCI
</org_name>
<org_full_name>
  National Cancer Institute (NCI)
</org_full_name>
<org_study_id>
  CDR0000067071
</org_study_id>
<secondary_id>
  NCCTG-982453
</secondary_id>
<nct_id>
  NCT00003900
</nct_id>
</study_id>
<brief_title>
<textblock>
  Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer
</textblock>
</brief_title>
<official_title>
<textblock>
  Phase II Study of Irinotecan With Docetaxel in Previously Treated Patients With Recurrent Non-Small Cell Lung Cancer
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  National Cancer Institute (NCI)
</agency>
</lead_sponsor>
<sponsor>
<agency>
  North Central Cancer Treatment Group
</agency>
</sponsor>
</study_sponsor>
<oversight_info>
<regulatory_authority>
  United States: Federal Government
</regulatory_authority>
</oversight_info>
<brief_summary>
<textblock>
  RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
           PURPOSE: Phase II trial to study the effectiveness of combining irinotecan and docetaxel in treating patients who have recurrent or metastatic non-small cell lung cancer.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
  OBJECTIVES: I.  Evaluate the response rate of previously treated patients with recurrent non-small cell lung cancer after treatment with irinotecan and docetaxel.
           II.  Determine the toxicity of this regimen in these patients.
           III. Determine the overall survival in this patient population.
 
 
 
 
 
           PROTOCOL OUTLINE: Patients receive irinotecan IV over 90 minutes immediately followed by docetaxel IV over 60 minutes on day 1. Treatment is repeated every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
           Patients are followed every 3 months for 5 years or until death.
 
 
 
 
        PROJECTED ACCRUAL:
  A total of 44 patients will be accrued for this study within 24 months.
</textblock>
</detailed_descr>
<status_block>
<status>
  No longer recruiting
</status>
<date>
  2004-04
</date>
</status_block>
<start_date>
<date>
  1999-10
</date>
</start_date>
<end_date>
<date>
</date>
</end_date>
<last_follow_up_date>
<date>
</date>
</last_follow_up_date>
<last_data_entry_date>
<date>
</date>
</last_data_entry_date>
<phase_block>
<phase>
  Phase 2
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<condition>
Stage IV  Non-Small Cell Lung Cancer 
</condition>
<condition>
Recurrent Non-Small Cell Lung Cancer 
</condition>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  docetaxel
</primary_name>
</intervention>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  irinotecan
</primary_name>
</intervention>
<eligibility>
<criteria>
<textblock>
  PROTOCOL ENTRY CRITERIA:
 
  --Disease Characteristics--
    - Histologically or cytologically confirmed non-small cell lung cancer (NSCLC); Reconfirmation of NSCLC required only if complete response for greater than 1 year
 
    - Measurable or evaluable disease
 
    - Tumor shrinkage or stability for at least 4 weeks on initial chemotherapy
 
    - CNS metastases allowed, if symptoms controlled for greater than 8 weeks after surgery or radiotherapy
 
  --Prior/Concurrent Therapy--
 
    - Biologic therapy: Not specified
 
    - Chemotherapy: See Disease Characteristics; No greater than 1 prior NSCLC chemotherapy regimen, excluding low dose cisplatin as a radiosensitizer; No prior irinotecan or docetaxel; At least 4 weeks since prior chemotherapy
 
    - Endocrine therapy: Not specified
 
    - Radiotherapy: See Disease Characteristics; At least 4 weeks since prior radiotherapy No prior radiotherapy to greater than 25% of bone marrow
 
    - Surgery: See Disease Characteristics
 
    - Other: No concurrent phenytoin, phenobarbital, or other anticonvulsants
 
  --Patient Characteristics--
 
    - Age: 18 and over
 
    - Performance status: 0-1
 
    - Life expectancy: At least 12 weeks
 
    - Hematopoietic: Absolute neutrophil count at least 1,500/mm3; Platelet count at least 100,000/mm3
 
    - Hepatic: Bilirubin normal; AST no greater than 2 times upper limit of normal (ULN)
 
    - Renal: Creatinine no greater than 2.5 times ULN
 
    - Cardiovascular: No New York Heart Association class III or IV heart disease
 
    - Other: No active infection; At least 5 years since any other prior malignancy except curatively treated basal or squamous cell skin cancer, carcinoma in situ, or other cancers; No grade 2 or worse peripheral neuropathy; No uncontrolled diabetes mellitus; No other serious underlying disease; Not pregnant or nursing; Fertile patients must use effective contraception
</textblock>
</criteria>
<healthy_volunteers>
</healthy_volunteers>
<patients>
</patients>
<expected_enrollment>
</expected_enrollment>
<gender>
</gender>
<minimum_age>
  18 Years
</minimum_age>
<maximum_age>
  N/A
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Chair
</role>
<name>
  Alex A. Adjei
</name>
<affiliation>
<agency>
  North Central Cancer Treatment Group
</agency>
</affiliation>
</investigator>
<location>
<facility>
<name>
  CCOP - Scottsdale Oncology Program
</name>
<address>
<city>
  Scottsdale
</city>
<state>
  Arizona
</state>
<zip>
  85259-5404
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Tom Robert Fitch
</name>
<phone>
  480-301-8296
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  CCOP - Carle Cancer Center
</name>
<address>
<city>
  Urbana
</city>
<state>
  Illinois
</state>
<zip>
  61801
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Kendrith M. Rowland, Jr.
</name>
<phone>
  217-383-3010
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  CCOP - Illinois Oncology Research Association
</name>
<address>
<city>
  Peoria
</city>
<state>
  Illinois
</state>
<zip>
  61602
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  John W. Kugler
</name>
<phone>
  309-671-3605
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  CCOP - Cedar Rapids Oncology Project
</name>
<address>
<city>
  Cedar Rapids
</city>
<state>
  Iowa
</state>
<zip>
  52403-1206
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Martin Wiesenfeld
</name>
<phone>
  319-363-8303
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  CCOP - Iowa Oncology Research Association
</name>
<address>
<city>
  Des Moines
</city>
<state>
  Iowa
</state>
<zip>
  50309-1016
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Roscoe F. Morton
</name>
<phone>
  515-282-2921
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Siouxland Hematology-Oncology
</name>
<address>
<city>
  Sioux City
</city>
<state>
  Iowa
</state>
<zip>
  51101-1733
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  John C. Michalak
</name>
<phone>
  712-252-0088
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  CCOP - Wichita
</name>
<address>
<city>
  Wichita
</city>
<state>
  Kansas
</state>
<zip>
  67214-3882
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Shaker R. Dakhil
</name>
<phone>
  316-262-4467
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  CCOP - Duluth
</name>
<address>
<city>
  Duluth
</city>
<state>
  Minnesota
</state>
<zip>
  55805
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  James Edward Krook
</name>
<phone>
  218-786-8364
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  CCOP - Metro-Minnesota
</name>
<address>
<city>
  Saint Louis Park
</city>
<state>
  Minnesota
</state>
<zip>
  55416
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Patrick J. Flynn
</name>
<phone>
  612-863-8585
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  CentraCare Clinic
</name>
<address>
<city>
  Saint Cloud
</city>
<state>
  Minnesota
</state>
<zip>
  56303
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Harold E. Windschitl
</name>
<phone>
  320-252-5131
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Mayo Clinic Cancer Center
</name>
<address>
<city>
  Rochester
</city>
<state>
  Minnesota
</state>
<zip>
  55905
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Alex A. Adjei
</name>
<phone>
  507-284-2511
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  CCOP - Missouri Valley Cancer Consortium
</name>
<address>
<city>
  Omaha
</city>
<state>
  Nebraska
</state>
<zip>
  68131
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  James A. Mailliard
</name>
<phone>
  402-398-6064
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Altru Health Systems
</name>
<address>
<city>
  Grand Forks
</city>
<state>
  North Dakota
</state>
<zip>
  58201
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Daniel J. Walsh
</name>
<phone>
  701-780-6390
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  CCOP - Merit Care Hospital
</name>
<address>
<city>
  Fargo
</city>
<state>
  North Dakota
</state>
<zip>
  58122
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Ralph Levitt
</name>
<phone>
  701-234-7592
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Quain &amp; Ramstad Clinic, P.C.
</name>
<address>
<city>
  Bismarck
</city>
<state>
  North Dakota
</state>
<zip>
  58501
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Ferdinand E. Koranteng-Addo
</name>
<phone>
  701-323-5200
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  CCOP - Toledo Community Hospital Oncology Program
</name>
<address>
<city>
  Toledo
</city>
<state>
  Ohio
</state>
<zip>
  43623-3456
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Paul L. Schaefer
</name>
<phone>
  419-479-5605
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  CCOP - Sioux Community Cancer Consortium
</name>
<address>
<city>
  Sioux Falls
</city>
<state>
  South Dakota
</state>
<zip>
  57105-1080
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Loren K. Tschetter
</name>
<phone>
  605-330-6510
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Rapid City Regional Hospital
</name>
<address>
<city>
  Rapid City
</city>
<state>
  South Dakota
</state>
<zip>
  57709
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Larry P. Ebbert
</name>
<phone>
  605-341-8901
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Saskatchewan Cancer Agency
</name>
<address>
<city>
  Regina
</city>
<state>
  Saskatchewan
</state>
<zip>
  S4S 6X3
</zip>
<country>
  Canada
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Maria R.B. Tria Tirona
</name>
<phone>
  306-766-2691
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<see_also>
<annotation>
<textblock>
  Clinical trial summary from the National Cancer Institute&apos;s PDQ&#174; database
</textblock>
</annotation>
<url>
  http://cancer.gov/clinicaltrials/NCCTG-982453
</url>
</see_also>
<keyword>
  adult solid tumor
</keyword>
<keyword>
  body system/site cancer
</keyword>
<keyword>
  cancer
</keyword>
<keyword>
  genetic condition
</keyword>
<keyword>
  lung cancer
</keyword>
<keyword>
  non-small cell lung cancer
</keyword>
<keyword>
  recurrent non-small cell lung cancer
</keyword>
<keyword>
  solid tumor
</keyword>
<keyword>
  stage IV non-small cell lung cancer
</keyword>
<keyword>
  stage, non-small cell lung cancer
</keyword>
<keyword>
  thorax/respiratory cancer
</keyword>
<initial_release_date>
  1999-11-01
</initial_release_date>
<last_release_date>
  2005-06-23
</last_release_date>
</clinical_study>
